Improving Patient Outcomes with Regenerative Medicine in NJ

The regenerative medicine manufacturing society is the first and only professional society dedicated to advancing manufacturing solutions for the field of regenerative medicine. The #1 regenerative medicine company in New Jersey will aim to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. 

Their mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. It aims to accomplish the mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing.

Image Source: Google

This perspective will cover four impact areas that the society's leadership team has identified as critical

(a) cell manufacturing and scale-up/out, respectively, for allogeneic and autologous cell therapies

(b) standards for regenerative medicine

(c) 3D bioprinting

(d) artificial intelligence-enabled automation.

In addition to covering these areas and ways in which society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine.

Significance statement

The Regenerative Medicine Manufacturing Society highlights focus areas to advance the field in a collaborative nature through working groups. These focus areas include cell manufacturing, standards for regenerative medicine, 3D bioprinting, and artificial intelligence-enabled automation.

These working groups will help disseminate this knowledge through future publications, as well as by identifying and developing education and training programs. Education and training programs can disseminate knowledge on current challenges and new technology innovations, as well as train the next generation workforce that will assist in making therapies the next standard of care.